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The major strength of nuclear medicine imaging has
always been its high functional resolution, and a good
example of this is lymphoscintigraphy using radiocolloids to
map the location of the lymph node receiving direct lymph
drainage from a solid tumor site. Using this technique the one
or two sentinel nodes of the 1,000 or more nodes in the
patient are radiolabelled and clearly visible on lymphoscin-
tigraphy.1 This same technique, however, also nicely
illustrates a limitation of nuclear medicine images: their low
anatomical resolution. The surface location of these sentinel
nodes (SN) can be marked and we can measure the depth of
the SN from the skin, but the planar nuclear medicine images
provide no anatomical information.
Nuclear medicine images can be improved using single
photon emission computed tomography (SPECT), which
displays tomographic slices of the distribution of tracer in
the patient. SPECT was developed in the late 1960s by
Kuhl and Edwards in Philadelphia before computed
tomography (CT) scans were developed.2 SPECT images
were better than planar scans as there was improved image
contrast of pathological lesions, but anatomical data in
these images was still limited; when using SPECT scans in
lymphoscintigraphy it is almost nonexistent.
The limitations of this low anatomical resolution in
nuclear medicine images, whether planar or tomographic,
is dramatically illustrated in the case of 18F-flourodeoxy-
glucose (FDG) positron emission tomography (PET)
scanning. This method was developed in the 1970s and,
although of great interest to nuclear medicine physicians as
it displayed the glycolytic rate of tumors, it had little
impact on clinical practice as clinicians had no confidence
in the information.3 Very little anatomical data was present
even in the three-dimensional (3D) tomographic PET dis-
plays. It was not until hybrid imaging devices were
produced that allowed PET/CT scans to be performed
without moving the patient that the situation changed.4
PET/CT allowed precise image fusion of the PET
tomographic slices with the corresponding CT anatomic
slices with the PET functional data displayed in color
against the grey scale background of the CT image.
Immediately clinicians could appreciate the importance of
the information in these images and PET/CT has now
assumed a major role in the staging of solid tumors and in
the detection of recurrence. These scans can also be used to
monitor the effectiveness of chemotherapy regimens by
directly measuring the metabolic activity of the tumor.
It is already clear that the equivalent technology for
single photon emitting radionuclides, SPECT/CT, is going
to have a similar impact on the clinical usefulness of these
tracers. SPECT/CT as part of lymphoscintigraphy is an
excellent example of the fusion of the high functional
resolution of nuclear medicine images (the radiolabelled
SN) with the high anatomical resolution of CT. The tech-
nology shows precisely which node is the SN, and its
detailed anatomical position can be described.
Several studies have shown that, in patients with mela-
noma, SPECT/CT provides advantages over planar
imaging. These include higher sensitivity for SN detection,
detection of SNs in new node fields, improved detection of
SNs when near the injection site, detection of deep pelvic
SNs in patients with leg melanomas, and improved surgical
location by providing exact anatomical location.5–7 The
study in this issue by van der Ploeg and colleagues, in a
group of patients with melanoma with a planar study that
was difficult to interpret, an unusual drainage pattern or no
drainage to a SN, confirmed increased sensitivity for
detecting the SN and also improved anatomical location
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that altered the surgical approach in 30% of patients
involving a different incision, an incision at another site or
an extra incision.8 The use of 3D volume-rendered images
should enhance the presentation of this data for the oper-
ating surgeon.
It is known that the skin can also drain through the body
wall to deeply placed SNs in some patients, and SPECT/CT
will clearly aid in the surgical location of such nodes.9 This
pattern most often occurs from the skin of the posterior loin
through the posterior body wall to retroperitoneal or par-
avertebral SNs, and a recent patient of The Sydney
Melanoma Unit who showed this drainage to a paraverte-
bral node had this node successfully removed using the
information obtained from his SPECT/CT lymphoscintig-
raphy. It is for this reason that SPECT/CT is likely to be
especially useful for imaging the SNs in patients with
tumors of the internal organs, though technical difficulties
need to be overcome for the problem of injecting the ra-
diocolloid to allow imaging prior to surgery.
One issue that is becoming more often discussed in the
diagnostic imaging literature is the dosimetry of these
procedures, especially when hybrid devices are used. The
key information that the CT image brings to the SPECT/CT
interpretation is the precise anatomical location of the
functional index lesion seen on the nuclear medicine
SPECT image. A high-dose CT is not required to give this
location and I would encourage all using SPECT/CT
hybrid imaging to use the lowest CT dose possible in each
patient. A high-dose diagnostic CT is simply not needed to
get the benefits of SPECT/CT, as it is the precise location
of the ‘‘hot spot’’ that is the vital data. This comment
applies equally to PET/CT. There will be occasions when a
follow-up high-dose diagnostic CT is needed, but they will
be few and quite rare when using SPECT/CT as part of
lymphoscintigraphy in patients with melanoma.
As a final comment it is important to remember that
SPECT/CT alone cannot replace the vital information
obtained during dynamic lymphoscintigraphy in patients
with melanoma. The identification of the individual lym-
phatic collectors reaching the SN on such images is the
most accurate method of designating a SN versus a second-
tier node that subsequently receives the radiocolloid. Other
useful information that is present on dynamic imaging and
not SPECT/CT is the dynamic arrival time of the tracer in
the SN, and the number of lymphatic collectors leaving the
melanoma site, which is a guide to the number of expected
SNs and the lymph node fields to which the collectors
drain. The relative intensity of the nodes is also best
illustrated on planar scans. Although a second-tier node
may appear well radiolabelled on SPECT/CT, it should not
be designated a SN and such a node should not be removed
as part of a SN biopsy procedure. To do so would negate
the important benefit of SN biopsy, that is, unprecedented
nodal staging with minimal morbidity.
SPECT/CT as part of lymphoscintigraphy in patients
with melanoma to locate the SN prior to surgical removal is
the future, and is here with clear benefits in many patients.
We must not abandon dynamic lymphoscintigraphy, how-
ever, as we would then be in grave danger of ‘‘throwing the
baby out with the bathwater’’ and compromising the great
benefits in lymph node staging that have already been
achieved using this technology.
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